NCT03276572View on ClinicalTrials.gov

Phase I Trial of 225Ac-J591 in Patients With mCRPC

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

January 7, 2021

Study Completion Date

September 1, 2023

Conditions
Prostate Cancer
Interventions
DRUG

225Ac-J591

225Ac-J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1

Trial Locations (2)

10065

Weill Cornell Medical College, New York

70112

Tulane Cancer Center Clinic, New Orleans

All Listed Sponsors
collaborator

Prostate Cancer Foundation

OTHER

collaborator

United States Department of Defense

FED

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Weill Medical College of Cornell University

OTHER

NCT03276572 - Phase I Trial of 225Ac-J591 in Patients With mCRPC | Biotech Hunter | Biotech Hunter